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Abstract
Background: The clinical significance of Coronavirus disease 2019 (COVID-19) as an
associate of myocardial injury is controversial.
Hypothesis: Type 2 MI/Myocardial Injury are associated with worse outcomes if
complicated by COVID-19.
Methods: This longitudinal cohort study involved consecutive patients admitted to a
large urban hospital. Myocardial injury was determined using laboratory records as
≥1 hs-TnI result >99th percentile (male: >34 ng/L; female: >16 ng/L). Endotypes were
defined according to the Fourth Universal Definition of Myocardial Infarction
(MI) and COVID-19 determined using PCR. Outcomes of patients with myocardial
injury with and without COVID-19 were assessed.
Results: Of 346 hospitalized patients with elevated hs-TnI, 35 (10.1%) had
laboratory-confirmed COVID-19 (median age [IQR]; 65 [59–74]; 64.8% male
vs. COVID-19 negative: 74 [63–83] years; 43.7% male). Cardiac endotypes by
COVID-19 status (yes vs. no) were: Type 1 MI (0 [0%] vs. 115 [100%]; p < .0005),
Type 2 MI (13 [16.5%] vs. 66 [83.5%]; p = .045), and non-ischemic myocardial injury
(cardiac: 4 [5.8%] vs. 65 [94.2%]; p = .191, non-cardiac:19 [22.9%] vs. 64 [77.%];
p < .0005). COVID-19 patients had less comorbidity (median [IQR] Charlson Comor-
bidity Index: 3.0 [3.0] vs. 5.0 [4.0]; p = .001), similar hs-TnI concentrations (median
[IQR] initial: 46 [113] vs. 62 [138]; p = .199, peak: 122 [474] vs. 79 [220] ng/L;
p = .564), longer admission (days) (median [IQR]: 14[19] vs. 6[12]; p = .001) and
higher in-hospital mortality (63.9% vs. 11.3%; OR = 13.2; 95%CI: 5.90, 29.7).
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Conclusions: Cardiac sequelae of COVID-19 typically manifest as Non-cardiac myo-
cardial injury/Type 2MI in younger patients with less co-morbidity. Paradoxically, the
admission duration and in-hospital mortality are increased.
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1 | INTRODUCTION
Coronavirus disease 2019 (COVID-19) is a novel cause of myocardial
injury.1 The importance of elevated cardiac troponin I (cTnI) in
patients requiring intensive care has been extensively documented.2,3
What is less well understood is the clinical significance of troponin
elevation in COVID-19 including in comparison with other causes of
myocardial injury.
Cardiovascular involvement is observed in approximately 25%
of patients with COVID-19. Myocardial injury may be due to primary
viral infection, secondary hypoxia, inflammatory state, hypotension,
thromboembolism, or a combination of these problems.4 Mechanis-
tic studies of the cardiac and multisystem effects of COVID-19
infection are on-going (ClinicalTrials.gov identifier NCT04403607).5
Non-ischemic myocardial injury (cardiac or non-cardiac) and Type
2 myocardial infarction (T2MI) generally portend an adverse progno-
sis, however, evidence-based treatment options are less well
established than is the case for Type 1 MI. Troponin-I elevation is
associated with fatal outcomes, however the etiology of this eleva-
tion is unclear..6
We prospectively investigated a population of consecutively
admitted patients with myocardial injury in relation to COVID-19 sta-
tus. We hypothesized that in patients with myocardial injury, COVID-
19 would associate with Type 2 MI more so than with other end-
otypes, and this combination would be an adverse prognostic factor
for in-hospital outcomes.
2 | METHODS
2.1 | Study design
This was a prospective, longitudinal cohort study involving hospi-
talized patients admitted to the Queen Elizabeth University Hospi-
tal, Glasgow, UK; an urban academic medical center (catchment
population 650 000) between March 1 and April 15, 2020. The
study protocol and proforma were predefined and Caldicott guard-
ian approval for the use of patient identifiable data was obtained
before starting the project. Routinely collected (usual care) data
were gathered by clinicians who were members of the usual care
medical team and ethics approval or explicit patient consent was
not required.
Consecutive patients who had a ≥1 hs-TnI measurement (Abbott
Architect TnI assay) >99th percentile sex-specific upper reference
limit (URL; male: >34 ng/L; female: >16 ng/L) were included in the
cohort. The troponin-I test was requested by the clinical team respon-
sible for the patients' care based on clinical suspicion of myocardial
injury by. The troponin test was not undertaken routinely on all
admissions, nor on all patients with COVID-19. A retrospective analy-
sis of electronic patient records (NHS Greater Glasgow and Clyde:
Clinical Portal, TrakCare systems) was performed. Source patient
details, including demographic, routine laboratory and clinical data
were evaluated in real-time by a team of acute medical physicians
(M.B., T.K., O.P., R.S.) and supervised by two senior cardiologists
(K.M., C.B,). Index admissions for all patients ≥18-years were consid-
ered; patients <18-years or with incomplete or missing data were
excluded.
Clinical endotypes of myocardial injury were defined according to
the Fourth Universal Definition of Myocardial Infarction (MI) and sub-
categorized according to etiology by inciting event (cardiovascular and
non-cardiovascular). In case of diagnostic ambiguity, endotypes were
assigned according to investigator consensus agreement following dis-
cussion with senior authors CB and KM.
2.2 | Diagnosis of COVID-19
A diagnosis of COVID-19 was determined by either laboratory evi-
dence of SARS-CoV-2 infection by PCR biospecimen testing and/or a
radiological diagnosis (chest computed tomography, chest radiograph)
consistent with COVID-19 but biospecimen negative with a clinical
presentation in keeping with SARS-CoV-2 infection. The laboratory
tests used were either the Roche Cobas 6800 or Seegene SARS-
CoV-2 tests.
2.3 | Statistics
Patients were dichotomized by COVID-19 status (positive or nega-
tive) and statistical analysis performed using IBM Statistics SPSS (ver-
sion 24.0). Chi-square (or Fisher's exact test) and odds ratios are
calculated for categorical characteristic variables and Mann–Whitney
U test for non-parametric independent continuous variables to assess
likelihood of association with COVID-19 status. Sub-group analyses
were performed defined by clinical endotype of hs-TnI elevation.
Mortality and readmission significance were assessed by Log-rank
(Mantel Cox) test and 95% two-tailed significance values provided. A
p-value of <.05 was considered significant.
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3 | RESULTS
Of 390 acutely hospitalized patients with elevated hs-TnI between
March 1–April 15, 2020, 346 were eligible for inclusion and 44 were
excluded at screening (Duplicates: 2; Missing data: 41; Research patient:
1). Type 1 myocardial infarction (T1MI) was diagnosed in 115 (33.2%)
patients, Type 2 MI/non-ischemic myocardial injury (non-cardiac) was
identified in 162 (46.8%) patients and myocardial injury of cardiac eti-
ology in 69 (19.9%) patients (Figure 1). The distribution of endotypes
within COVID positive and negative patients is presented in Tables S1
and S2.
Across all patient groups, 36 (10.4%) were diagnosed with
COVID-19. This included 35 (10.1%) laboratory-confirmed COVID-19
infection and one CT-diagnosed patient admitted to COVID-19 inten-
sive care. The young PCR negative patient required invasive ventila-
tion with peripherally-predominant ground glass opacities throughout
both lungs and negative microbiology and extended virology testing.
Overall, this represented 38.7% of the inpatient laboratory-confirmed
COVID-19 positive patients (n = 93) at our site during the study
period. A combination of ECG findings and clinical assessment form
the basis for diagnosis of Type 1 MI patients in our initial study popu-
lation, of which no patients were concomitantly diagnosed with
COVID-19. The distributions of cardiac endotypes by COVID-19 sta-
tus (yes vs. no) were: Type 1 MI (0 [0%] vs. 115 [100%]; p < .0005),
Type 2 MI (13 [16.5%] vs. 66 [83.5%]; p = .045), and non-ischemic
myocardial injury (cardiac: 4 [5.8%] vs. 65 [94.2%]; p = .191, non-car-
diac:19 [22.9%] vs. 64 [77.1%]; p < .0005). As no COVID-19 positive
patients were assigned a diagnosis of Type 1 MI, these were excluded
from further analysis. In total, 232 patients with Type 2 MI (T2MI) or
non-ischemic myocardial injury (cardiac or non-cardiac) were analyzed
with dichotomization by COVID-19 status.
3.1 | Patient characteristics
The characteristics of patients with COVID-19 infection and Type
2 MI or myocardial injury compared with those without COVID-19
infection are described in Table 1. Among all patients, those with
COVID-19 were younger (median age [interquartile range];
65 [59–74] vs. 74 [63–83] years) and 64.8% vs. 43.7% were male
(p = .058). Patients with a diagnosis of COVID-19 had comparable
average hs-TnI concentrations with COVID-19 negative patients
(median [interquartile range] initial hs-TnI: 41 [106] vs. 61 [137] ng/L;
p = .199, peak hs-TnI: 121 [230] vs. 78 [204] ng/L; p = .564) (Table 1
and Table S4). Patients with COVID-19 had a lower comorbidity bur-
den (median [IQR] Charlson Comorbidity Index [CCI]: 3.0 [3.0] vs. 5.0
[4.0]; p = .001). Heart failure, chronic kidney disease (CKD), and
chronic hematological disease were less common in patients with ele-
vated cTnI and COVID-19 infection; but obesity was significantly
more prevalent when compared with COVID-19 negative patients
(44.4% vs. 14.9%, odds ratio [OR]: 4.58, 95% CI: 2.13, 9.86).
Respiratory failure requiring invasive mechanical ventilation (IMV)
occurred in 20 (55.6%) patients with COVID-19, whilst 14 (38.9%)
and 17 (47.2%) required renal and/or circulatory support, respectively.
Compared with patients who are COVID-19 negative, there is no sig-
nificant difference in initial or peak troponin-I values independent of
ventilation status, renal and/or circulatory support (Table 2).
Troponin-I values within the COVID-19 positive were not significantly
F IGURE 1 Flow diagram
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different for initial or peak hs-TnI for patients requiring IMV compared
with supplementary oxygen (O2) (Initial median [IQR] hs-TnI:
IMV = 33 [55] ng/L vs. O2 = 34 [50] ng/L, p = .559; Peak median
[IQR]) hs-TnI: IMV = 103.5 [133]) ng/L vs. O2 = 70.5 [114] ng/L,
p = .183). COVID-19 positive patients who required renal replacement
therapy (RRT) had comparable initial hs-TnI (RRT median [IQR] = 35.5
[74] ng/L vs. no RRT median [IQR] = 36 [43] ng/L, p = .986) and peak
hs-TnI (median [IQR] = 97 [243] ng/L vs. 69.5 [81] ng/L, p = .259).
3.2 | 12-lead electrocardiogram (ECG)
Of all included patients, three did not have a 12-lead ECG available for ret-
rospective assessment on digital patient records of which one was
COVID-19 positive. This patient had a maximal troponin I of 43 ng/L
(median 16 [IQR: 24.5]) during ITU admission on continuous 3-lead ECG
monitoring and categorized as non-cardiac myocardial injury. The two
patients in the COVID-19 negative group without 12-lead ECG were:
TABLE 1 Characteristics of hospitalized patients with myocardial injury defined by a high sensitivity troponin plasma concentration > URL
described according to COVID-19 status (Odds Ratio/Mean difference)
Variable COVID +ve COVID -ve
OR (95% CI) p Value(N = 232) (n = 36) (n = 195)
Age - median [IQR] 65.0 (5.0) 74.0 [20.0] - .009
Female 13 (36.1%) 104 (53.3%) 0.50 (0.24, 1.03) .058
Ethnicitya .82
Arab 0 (0.0%) 1 (0.5%)
South Asian 1 (2.8%) 2 (1.0%)
West Asian 1 (2.8%) 5 (2.6%)
White 34 (94.4%) 187 (95.9%)
Died during admission (n = 46) 23 (63.9%) 23 ([11.3%) 13.9 (6.18, 31.3) <.001
Overall mortality from admission to follow-up (n = 60) 23 (63.9%) 37 (19.0%) 7.56 (3.50, 16.3) <.001
Duration admission - median [IQR] 14.0 (19.0) 6.0 (12.0) - <.001
Survivors with unplanned readmission~ (n = 43) 3 (8.3%) 40 (23.1%) 0.35 (0.10, 1.21) .104
Days until unplanned readmission (n = 43) - median [range] 24 [22] 17.5 (64) - .451
Initial troponin - median [IQR] 41 [106] 61 [137] - .199
Peak troponin - median [IQR] 121 [230] 78 [204] - .564
Past medical history
Heart failure 7 (19.4%) 94 (48.2%) 0.26 (0.11, 0.62) .001
Chronic pulmonary disease (not asthma) 10 (27.8%) 45 (23.1%) 1.28 (0.58, 2.86) .543
Asthma 4 (11.1%) 25 (12.8%) 0.85 (0.28, 2.61) .776
Chronic kidney disease 4 (11.1%) 74 (37.9%) 0.20 (0.07, 0.60) .002
Liver disease 0 (0.0%) 4 (2.1%) 1.02 (1.00, 1.04) 1
Chronic neurological disorder 1 (2.8%) 10 (5.1%) 0.53 (0.07, 4.26) 1
Malignant Neoplasm 2 (5.6%) 28 (14.4%) 0.35 (0.08, 1.54) .185
Chronic hematological disease 0 (0.0%) 10.3% 0.90 (0.85, 0.94) .05
Obesity 16 (44.4%) 29 (14.9%) 4.58 (2.13, 9.86) <.001
Diabetes mellitus 10 (27.8%) 47 (24.1%) 1.21 (0.54, 2.70) .638
Connective tissue disorder 3 (8.3%) 10 (5.1%) 1.68 (0.44, 6.44) .433
Dementia 2 (2.8%) 13 (6.7%) 0.40 (0.05, 3.16) .702
History of smoking 22 (61.1%) 104 (53.3%) 1.38 (0.67, 2.84) .389
Current 4 (11.1%) 39 (20.0%) 0.50 (0.17, 1.50) .208
Previous 18 (50.0%) 65 (33.3%) 2.00 (0.98, 4.10) .056
Never 14 (38.9%) 91 (46.7%) 0.73 (0.35, 1.50) .389
Peripheral vascular disease 0 (0.0%) 2 (1.0%) 1.01 (1.00, 1.03) 1
Charlson comorbidity index - median [IQR] 3.0 [3.0] 5.0 [4.0] - .001
Charlson comorbidity index estimated 10-year survival -
median [IQR]
77.0% (69.0%) 21.0% (77.0%) - .001
aNone of the patients had Black, East Asian or Latin American ethnic backgrounds.
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(1) a dialyzed patient with superadded diagnosis of UTI and elevated tro-
ponin; and (2) an agitated patient with dementia and infective exacerba-
tion of chronic airways disease who did not tolerate 12-lead ECG
assessment. In the remaining 343 patients from the initial cohort, ECGs
were reviewed by emergency and internal physicians when obtained and
uploaded to digital patient record for retrospective review by the study
authors. Cardiology opinion was sought where clinically required by usual
care teams but was not requested routinely for each patient. Senior
authors (CB and KM) are experienced Cardiologists and any dubiety in
diagnosis was explored with them, and consensus made if necessary.
The ECG features are described in Table S3, including patients
with a diagnosis of Type 1 MI from the initial cohort.
Patients with Type 2 MI or myocardial injury, less frequently
underwent further coronary assessment with either CT coronary angi-
ography (n = 5) or invasive catheter angiography (n = 6). Cardiac MRI
was performed in patients with a diagnosis of myocarditis in addition
to clinical and ECG assessment.
3.3 | Cardiac myocardial injury in COVID-19
Physiological stress-induced cardiac myocardial injury (i.e., hemodynamic
shock, invasive ventilation, inotropic therapy) was the most prevalent
cause for patients with COVID-19 infection (27.8% vs. 3.5%, p < .001).
Myocarditis/pericarditis was listed as causative in 8.3% COVID-19 posi-
tive patients compared to 2.9% of all COVID-19 negative patients
(p = .116). Hypotension (8.3%) and hypertension (2.8%) were also impli-
cated as causal associations for myocardial injury in the COVID-19 posi-
tive patients, however these were not significant between groups
(Figure 2 and Table S1). Cardiac causes of myocardial injury (Table S1)
were more common in patients without COVID-19 (positive: 11.1%
vs. negative: 33.3%, p = .022), of which tachyarrhythmia and heart failure
were the most likely mechanisms (15.7% and 15.1% respectively).
3.4 | Non-cardiac myocardial injury or Type
2 myocardial infarction in COVID-19
Within this cohort, hypoxia was the most likely (OR: 7.96; 95% CI: 3.64,
17.4) contributing mechanism to non-cardiac myocardial injury or Type
2 MI in patients with COVID-19 (52.8%) compared with COVID-19
negative patients (12.3%) (p < .001). Anemia was also significantly more
likely in COVID-19 positive patients (38.9% vs. 22.6%, OR: 2.18, 95%
CI: 1.03, 4.62). Non-COVID-19 infection was the most common etiol-
ogy in COVID-19 negative patients (37.9%) and superadded infection in
COVID-19 positive patients was less common (5.6%) (OR: 0.1, 95% CI:
0.02, 0.41). Acute renal impairment (with or without underlying renal
disease) was comparable between COVID status groups (positive:
33.3% vs. negative: 29.7%, p = .667) (Figure 3 and Table S2).
3.5 | Outcomes of patients with elevated cTnI in
COVID-19
Vital status was determined in all patients by assessment of electronic
patient records. The duration of follow-up was a median of 71 days (inter-
quartile range: 29.3, minimum: 0, maximum: 151 days) from date of
admission. Overall, 73 (21%) patients died within this period. Patients
who tested positive for COVID-19 with elevated cTnI had a longer hospi-
tal stay (median [IQR]: 14 [19] vs. 6 [12]; p < .001) and higher inpatient
mortality (63.9% vs. 11.3%; OR = 13.2; 95% CI: 5.90, 29.7) compared
with negative patients. Index CCI 10-year survival estimates were greater
in patients with COVID-19 compared with COVID-19 negative patients
(77.0% vs. 21.0% alive at 10 years, p < .001). Unplanned readmissions
occurred in 43 patients in all groups however there was no significant dif-
ference in frequency (positive: 8.3% vs. negative: 20.5%, p = .104) or
duration until readmission (median = positive: 24.0 [IQR: 22.0]
vs. negative: 17.5 [IQR: 64.0]; p = .292) between groups.
4 | DISCUSSION
We have provided novel information on the nature and clinical signifi-
cance of COVID-19 in a hospitalized population with myocardial
injury.
Our study involved prospective clinical evaluation of consecutive
patients in real-time during the study period. Cases of myocardial
injury were identified based on a high sensitivity troponin result
>URL. This approach was intended to minimize missing data and
selection bias. We found that the cardiac sequelae of COVID-19
TABLE 2 Median [IQR] high sensitivity troponin I values (ng/L) for hospitalized patients with increased troponin and COVID-19 stratified by
ventilation status and renal or circulatory support compared with COVID-19 negative patients
Initial hs-TnI median [IQR] p value Peak hs-TnI median [IQR] p value
COVID negative (n = 195) 62 [138] (n = 195) 79 [220] -
COVID positive (n = 33) 46 [113] .199 (n = 36) 122 [474] .564
Supplementary oxygen (n = 30) 34 [50] .213 (n = 30) 70.5 [114] .635
Invasive mechanical ventilation (n = 20) 33 [55] .821 (n = 20) 103.5 [133] .326
Inotropic support (n = 17) 34 [53] .683 (n = 17) 76 [186] .610
Hemodialysis (n = 14) 35.5 [74] .986 (n = 14) 97 [243] .259
Note: p-value represents the comparison of COVID-19 positive patients with Type 2 MI/Myocardial Injury and subgroups compared with COVID-19
negative patients with Type 2 MI/Myocardial Injury.
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typically present as Type 2 MI or non-cardiac myocardial injury; no
patients presented with COVID-19 infection and Type 1 MI during
the study period. Compared to patients with myocardial injury with-
out COVID-19, patients with COVID-19 and myocardial injury were
younger and had fewer concomitant health problems (including a
lower Charlson Comorbidity Index). By contrast, they had significantly
greater in-hospital mortality and a longer inpatient stay despite com-
parable hs-TnI at baseline and peak values.
As has been widely reported, obesity is significantly associated
with COVID-19 and T2MI/non-ischemic myocardial injury as opposed
to non-COVID-19 etiologies of hs-TnI elevation. Troponin elevation
in a hospitalized population with COVID-19 may provide information
on disease severity and the poorer outcomes observed in this study
are in keeping with existing literature (6). Non-COVID-19 etiologies
included bacterial infection, tachyarrhythmia and heart failure. Hyp-
oxia was the most likely contributing mechanism in patients with
COVID-19 in keeping with the common respiratory manifestations of
this disease. Anemia was also more common in COVID-19 patients
with myocardial injury/Type 2 MI. There was no significant difference
in incidence of pulmonary embolism, impaired renal status or presence
of diabetes in this cohort of patients with myocardial injury/Type
2 MI regardless of COVID-19 status however, the small number of
troponin positive patients with these factors limits power in this study
to detect a significant difference.
4.1 | Implications for etiology of myocardial injury/
Type 2 MI in COVID-19 positive patients
We found that the hs-TnI concentrations were broadly similar in the
COVID-19 and non-COVID-19 subgroups, although in-hospital mor-
tality was greater in COVID-19 positive patients. In the context of
(A)
(B)
F IGURE 2 Proportion of
cardiovascular causes of myocardial injury
in COVID-19 positive (A; n = 4) and
negative (B; n = 65) patients
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COVID-19, Type 2 MI/Myocardial injury was observed in younger,
less co-morbid patients. Hypoxia, anemia and renal dysfunction are
also clearly relevant complications. This is in keeping with emerging
autopsy reports of multi-organ failure due to septic shock with respi-
ratory infection being most common cause of death.7
There were no instances of tachyarrhythmia documented as the
cause of hs-TnI elevation in the 36 patients with COVID-19 however
three positive patients were noted to have existing atrial fibrillation
with a maximum 12-lead ECG rate of 131 bpm. Since continuous ECG
monitoring data were not available, this finding may represent an
under-estimate. In prior studies, arrhythmia may be present in up to
44% of patients with severe illness. Case reports from other pandemic
regions have included arrhythmias in the peri-mortem stage of illness
or secondary to hypoxemia mediated conduction deficits.8,9 Further
information on 12-lead ECG observations in positive and negative
patients is provided in Table S3.
Pericarditis/Myocarditis was recorded as the mechanism of myo-
cardial injury in three patients with COVID-19. Diagnosis was made
on clinical suspicion with ECG changes and cardiac MRI as objective
confirmation of diagnosis. Myocarditis in COVID-19 has been
reported previously – although uncommonly – and the results of pro-
spective imaging studies will potentially illuminate the prevalence in
surviving patients following COVID-19 infection.10
Obesity was the most common co-morbidity within our cohort,
observed among 44.4% of patients with COVID-19 and Type
2 MI/myocardial injury. Obesity is associated with adverse outcomes
in COVID-19 infection.11-13 A combination of increased cardiac
demand and abnormalities of diastolic function in combination with
hypoventilation in respiratory illness and high prevalence of metabolic
disease are likely contributors..14,15
Type 2 MI/myocardial injury is associated with increased illness
severity as evidenced by significantly higher mortality and duration of
hospital stay.16 Though exact mechanisms of myocardial injury and
modifiable outcome in patients with COVID-19 is yet to be demon-
strated, protocolized high-sensitivity troponin testing and its utiliza-
tion in stratification could be a useful tool for early recognition of
adverse outcome and early decision making in this group.17
4.2 | Study limitations
Limitations of this study included a the moderate number of patients
with COVID-19 and concomitant hs-TnI elevation within our popula-
tion despite sampling during the first peak phase of disease activity in
our hospital. The limited number of COVID-19 patients with troponin
I may have an impact on the statistical power to detect differences in
hs-TnI values, that is, in patients requiring renal replacement therapy
with COVID-19 had an approximately 30% greater value (ng/L) but
this was not statistically significant. Troponin I is not routinely sam-
pled in patients who present with COVID-19 symptoms hence there
may be an under-representation of troponin elevation. Physiological
stress and myocarditis/pericarditis were documented as the most
prevalent causes of non-ischemic cardiovascular myocardial injury in
patients positive for COVID-19. Advanced cardiovascular imaging
(cardiac magnetic resonance imaging [CMRI], CT coronary angiogra-
phy [CTCA]) was not routinely feasible on logistical grounds during
the pandemic which may have led to a degree of under-reporting of
Type 1 MI.
4.3 | Conclusions
The occurrence of myocardial injury and COVID-19 is associated with
a high in-hospital mortality. Type 2 MI or myocardial injury in COVID-
19 infection has poorer in-hospital outcomes compared with other
causes of Type 2 MI or myocardial injury.
(A)
(B)
F IGURE 3 Proportion of Type 2 MI and non-cardiac of
myocardial injury in COVID-19 positive (A; n = 32) and negative (B;
n = 130) patients
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